RM175

Artner C, Holtkamp HU, Hartinger CG, Meier-Menches SM. Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay. J Inorg Biochem. 2017 Dec;177:322-327. doi: 10.1016/j.jinorgbio.2017.07.010. Epub 2017 Jul 16. PubMed PMID: 28739166. Bratsos I, Jedner S, Bergamo A, Sava G, Gianferrara T, Zangrando E, Alessio E. Half-sandwich Ru II[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity. J Inorg Biochem. 2008 May-Jun;102(5-6):1120-33. doi: 10.1016/j.jinorgbio.2008.01.005. Epub 2008 Jan 9. PubMed PMID: 18279961. Bergamo A, Gaiddon C, Schellens JH, Beijnen JH, Sava G. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. J Inorg Biochem. 2012 Jan;106(1):90-9. doi: 10.1016/j.jinorgbio.2011.09.030. Epub 2011 Sep 29. Review. PubMed PMID: 22112845. Bergamo A, Masi A, Peacock AF, Habtemariam A, Sadler PJ, Sava G. In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model. J Inorg Biochem. 2010 Jan;104(1):79-86. doi: 10.1016/j.jinorgbio.2009.10.005. Epub 2009 Oct 14. PubMed PMID: 19906432.